Oct 30, 2008
Notice
Kringle Pharma Achieved Permission to Conduct Phase 1 Clinical Studies on recombinant human HGF for the Treatment of ARF in US.
Kringle Pharma Achieved Permission to Conduct Phase 1 Clinical Studies on recombinant human HGF for the Treatment of ARF in US.
